ABEO News and Press, Abeona Therapeutics Inc. From 10/13/25

CLEVELAND, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that its ABO-503 gene therapy for X-linked retinoschisis (XLRS) has been selected to particip...

CLEVELAND, Ohio and AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Children's Hospital Colorado today announced activation of Children's Colorado as the newest Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellu...

2025-10-07 10:38:34 ET The last time I spoke about Spruce Biosciences ( SPRB ) was in a Seeking Alpha article entitled " Spruce Biosciences: H2 2023 Data Could Be A Game Changer For CAHT Treatment ". At that time I had a "Hold" rating on the belief that the company would...

2025-08-15 16:36:09 ET The last time I wrote about Abeona Therapeutics ( ABEO ) it was in a Seeking Alpha article entitled " Abeona: BLA Resubmission of Pz-Cel Gets Ball Rolling Towards Other Milestones. " With respect to this article, I noted the potential for this comp...

2025-08-14 08:41:37 ET More on Abeona Therapeutics Is Abeona Therapeutics' Zevaskyn Worth $3.1m Per Treatment, Or Will Krystal Biotech Remain The Market Leader? Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) Abeona sells Rare Pediat...

- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch on track and first ZEVASKYN pati...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Abeona Therapeutics Inc. (ABEO) is expected to report $-0.39 for Q2 2025

2025-08-10 18:45:13 ET Abeona Therapeutics Inc. (ABEO) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 7.47%. The average open to low on the day of earnings was -5.93%. The average open ...

2025-08-10 18:40:14 ET Abeona Therapeutics Inc. (ABEO) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in ABEO stock price following earnings has averaged ±2.43% , with a median of 1.61%....